Close

Antibody

Reduced Hospital Admission Seen in High-Risk COVID Patients Given Monoclonal Antibody Combo

NEW YORK (Reuters Health) – People with mild to moderate COVID-19 who were treated with casirivimab and imdevimab – two monoclonal antibodies with emergency-use authorization for COVID-19 in the U.S. – had lower hospitalization rates than untreated counterparts in a retrospective study. Dr. Raymund Razonable of Mayo Clinic, in Rochester, […]

Read More

7 Months After Infection, SARS-CoV-2 Antibody Levels Remain Stable or Even Increase

The levels of IgG antibodies against SARS-CoV-2 Spike protein remain stable, or even increase, seven months after infection, according to a follow-up study in a cohort of healthcare workers coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Hospital […]

Read More

FDA Okays Regeneron COVID-19 Antibody as Preventive in High-Risk Settings

The US Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc’s COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people. The company said the authorization enables the therapy to be used in people exposed to an infected individual, or […]

Read More

Fauci Says He Won’t Take an Antibody Test

America’s COVID-19 doctor, Anthony Fauci, MD, says he won’t bother taking an antibody test to find out whether he needs a coronavirus vaccine booster shot. “If I went to LabCorp or one of those places and said, ‘I would like to get the level of anti-spike antibodies,’ I could tell what my level is, if […]

Read More

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and the SARS-CoV-2 pandemic1–4. Vaccines that elicit protective immunity against SARS-CoV-2 and betaCoVs circulating in animals have the potential to prevent future betaCoV pandemics. Here, we show that macaque immunization with a multimeric SARS-CoV-2 […]

Read More

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Highlights Broad variation in neutralizing antibodies in SARS-CoV-2-convalescent individuals. ∼3% individuals showed a potent antibody response with SARS-CoV-1 cross-reactivity. Older age, symptomatic and severe disease predict higher SARS-CoV-2 neutralization. Serum and IgG neutralization half-lives were 14.7 and 31.4 weeks respectively. Summary Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the […]

Read More

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Summary Background Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. Methods A large, multicentre, prospective cohort study was done, […]

Read More

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

The efficacy of two injections of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna])1 in preventing symptomatic SARS-CoV-2 infection in persons without previous coronavirus disease 2019 (Covid-19) has been shown to be high. We wondered what the response would be to the […]

Read More